Stayble Therapeutics AB (OSTO:STABL) Total Liabilities : kr6.33 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB Total Liabilities?

Stayble Therapeutics AB's Total Liabilities for the quarter that ended in Sep. 2023 was kr6.33 Mil.

Stayble Therapeutics AB's quarterly Total Liabilities declined from Mar. 2023 (kr4.99 Mil) to Jun. 2023 (kr4.19 Mil) but then increased from Jun. 2023 (kr4.19 Mil) to Sep. 2023 (kr6.33 Mil).

Stayble Therapeutics AB's annual Total Liabilities increased from Dec. 2020 (kr2.45 Mil) to Dec. 2021 (kr3.83 Mil) and increased from Dec. 2021 (kr3.83 Mil) to Dec. 2022 (kr3.87 Mil).

Stayble Therapeutics AB Total Liabilities Historical Data

The historical data trend for Stayble Therapeutics AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Total Liabilities Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

1.89

10.02

2.45

3.83

3.87

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															3.86	3.87	4.99	4.19	6.33

Stayble Therapeutics AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stayble Therapeutics AB's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.016	+	(0	+	0.85
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.87

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	19.148	-	15.282
	=	3.87

Stayble Therapeutics AB's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.482	+	(0	+	0.85
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	6.33

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	29.128	-	22.796
	=	6.33

Stayble Therapeutics AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (OSTO:STABL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines